Dermatological
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Sales of Zoryve comfortably exceeded consensus in the third quarter and both the foam and cream formulations are selling well across its dermatological indications.
More deals could be on the way as the US giant is rumored to be eyeing the acquisition of its icotrokinra development partner.
The US biotech has raised $300m to advance its atopic dermatitis candidate towards Phase III trials next year.
The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.
The Swiss major's oral BTK inhibitor gets the green light in the US for chronic spontaneous urticaria.
The Swiss company remains bullish about the drug’s prospects for hidradenitis suppurativa but its stock has collapsed by 90% after hit-and-miss Phase III trial results.
The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.
Its Phase III data compare favorably with same-class Cosentyx and Bimzelx in hidradenitis suppurativa, and the company is now seeking a partner.
Ascletis presented updated results at EADV showing denifanstat could significantly improve acne conditions versus placebo in Chinese patients after four weeks of treatment.
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
The dual TNFα/OX40L drug comfortably beat placebo in reducing symptoms of hidradenitis suppurativa but no news on Phase III plans yet.
The EMA is reviewing the IL-23-targeting oral peptide which the company claims will transform the plaque psoriasis treatment paradigm.
The drug will face competition from established IL-17 therapies such as Cosentyx, Bimzelx and Taltz, while overall market growth is expected to be supported by newer interleukin inhibitors and rising prevalence.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.
The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.
The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.